(Q73310296)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

1 reference

1 reference

M G Neuman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J P Benhamou

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M Martinot

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

N Boyer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

N H Shear

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

I Malkiewicz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

G G Katz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A Suneja

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

S Singh

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

P Marcellin

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 October 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

published in

Clinical Biochemistry

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

537-545

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

cites work

Therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Injection site vasculitis in a patient receiving interferon alfa for chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Fibrillary glomerulonephritis associated with hepatitis C viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Extrahepatic immunologic features of chronic viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Effect of r-interferon alpha administration on hypothalamus-pituitary-thyroid axis in chronic hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Diabetes mellitus and chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

The spectrum of extrahepatic manifestations in hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case-controlled, hemodynamic study of 17 consecutive cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Changes in hepatitis C virus antigen in liver with antiviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Treatment of chronic viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Historical treatment of chronic hepatitis B and chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

7 January 2021

Cytokines and the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Naive and memory T cell infiltrates in chronic hepatitis C: phenotypic changes with interferon treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Monokine production by peripheral whole blood in chronic hepatitis C patients treated with interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Granulocyte-macrophage colony-stimulating factor as adjuvant therapy for factor as adjuvant therapy for interferon alpha treatment of chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Biological properties of interleukin-12 and its therapeutic use in persistent hepatitis B virus and hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Production of interleukins 10 and 12 by peripheral blood mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Liver-infiltrating and circulating CD4+ T cells in chronic hepatitis C: immunodominant epitopes, HLA-restriction and functional significance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-alpha in chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alpha (IFN-alpha) treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Profiles of cytokines produced by CD4-positive T lymphocytes stimulated by anti-CD3 antibody in patients with chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900053-3

10.1016/S0009-9120(99)00053-3

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10614716%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference